Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Trappsol

March 14, 2022 CD as API / Pharma applications

Cyclo Therapeutics on Phase 3 Clinical Development Program for Trappsol® Cyclo™ in Niemann-Pick Disease Type C

Businesswire published: Cyclo Therapeutics Announces Formation of Global Steering Committee Comprised of Leading Experts to Advise on the Global Phase

Continue reading

December 7, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Receives IND Clearance from the U.S. FDA to Advance its Phase 2 Study of Trappsol® Cyclo™ for the Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc. (Nasdaq: CYTH) (“Cyclo Therapeutics” or the “Company”), a clinical stage biotechnology company dedicated to developing life-changing medicines through

Continue reading

November 18, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Submits IND Application to U.S. FDA to Advance Trappsol® Cyclo™ in Phase 2 Study for Treatment of Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 29, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Design of Pivotal Phase 3 Study Evaluating Trappsol® Cyclo™ in Niemann-Pick Type C1

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 22, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics to Proceed with IND Filing for Phase 2 Trial Using Intravenous Trappsol® Cyclo™ in Alzheimer’s Disease

Cyclo Therapeutics, Inc., a clinical stage biotechnology company dedicated to developing life-changing medicines through science and innovation for patients and

Continue reading

April 1, 2021 CD as API / CD derivatives

Cyclo Therapeutics Meets Primary Efficacy Endpoint in Phase 1/2 Trial from Intravenous Trappsol® Cyclo™ in Rare Disease Niemann-Pick Type C1 (NPC1)

100% of patients who completed the trial improved or remained stable, and 89% met the efficacy outcome measure of improvement

Continue reading

February 11, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Presents Positive Data from Clinical Development Program for Lead Candidate, Trappsol® Cyclo™, at WORLDSymposium 2021

Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing cyclodextrin-based products for the treatment of Niemann-Pick Disease Type C and

Continue reading

January 8, 2021 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Announces Positive Efficacy Data in Patients with Niemann-Pick Disease Type C

Home-based intravenous infusions of Trappsol® Cyclo™ for up to one year show improvement in disease features or disease stabilization Cyclo

Continue reading

December 10, 2020 CD as API / Events / Pharma applications

Cyclo Therapeutics Announces Pricing of $12.5 Million Public Offering

Transaction Includes Uplisting to Nasdaq and Reverse Stock Split Cyclo Therapeutics, Inc., a clinical stage biotechnology company developing a cyclodextrin

Continue reading

October 19, 2020 CD as API / CD derivatives / Pharma applications

Cyclo Therapeutics Phase 3 Pivotal Program Can Begin Enrollment Per US FDA

Cyclo Therapeutics will now proceed in the US with its Phase 3 clinical trial of Trappsol® Cyclo™ for treatment of Niemann-Pick

Continue reading

Posts navigation

1 2 Next Posts»

Recent Posts

  • Mannose-modified methyl-β-cyclodextrin suppresses tumor growth
  • Cyclodextrin Based Polymeric Nanobeads
  • Coatings of Cyclodextrin/Citric-Acid Biopolymer as Drug Delivery Systems: A Review
  • α-CD as laxative for pets and CD as litter deodorant
  • 7th European Cyclodextrin Conference

Tags

alpha-CD antiviral Biotechnology Cancer therapy Captisol Cholesterol Clinical trial conference coronavirus Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems FDA Food Gilead History HPBCD Nanoparticles nanotechnology Niemann Pick Disease RAMEB remdesivir SBECD Special issue Sugammadex Synthesis wastewater treatment

Follow Us

  • LinkedIn
  • Twitter
  • Facebook

Categories

  • Agriculture (13)
  • Analysis (35)
  • CD as API (200)
  • CD derivatives (254)
  • Cosmetics and toilettry (21)
  • Drug delivery (418)
  • E-ducation (54)
  • Environmental (76)
  • Events (158)
  • Food (121)
  • Gene delivery (10)
  • In Hungarian (4)
  • Life sciences (13)
  • Non-pharma applications (210)
  • Other industrial use (58)
  • Pharma applications (680)
  • Supramolecular systems (25)
  • Uncategorized (41)

Top Posts

  • α-CD as laxative for pets and CD as litter deodorant
  • Cyclodextrin Based Polymeric Nanobeads
  • Lanosterol eye drops for cataract treatment
  • Coatings of Cyclodextrin/Citric-Acid Biopolymer as Drug Delivery Systems: A Review
  • International Symposium of Drug Delivery Systems (SDDS-2022)
  • 7th European Cyclodextrin Conference
  • Mannose-modified methyl-β-cyclodextrin suppresses tumor growth
  • Bacteroides uniformis and its preferred substrate, α-cyclodextrin, enhance endurance exercise performance in mice and human males
  • How air fresheners work?
  • GRAS status of CD derivatives

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 522 other subscribers
 

Loading Comments...